<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00637104</url>
  </required_header>
  <id_info>
    <org_study_id>IBS/03-2007</org_study_id>
    <nct_id>NCT00637104</nct_id>
  </id_info>
  <brief_title>European Multicenter, Randomized, Comparative Efficacy/Safety Study of the Mar-Tyn TiN-Coated Stent</brief_title>
  <acronym>MARTIN</acronym>
  <official_title>A European Multicenter, Randomized, Single Blind Study of the MAR-Tyn Cobalt Chromium TiN-Coated Balloon-Expandable Stent in the Treatment of Patients With de Novo Coronary Artery Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International Biomedical Systems S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>International Biomedical Systems S.p.A.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to assess the safety and effectiveness of the TiN-coated&#xD;
      MAR-Tyn stent in maintaining minimum lumen diameter in de novo native coronary artery lesions&#xD;
      as compared to an uncoated control cobalt-chromium balloon-expandable stent (Vision, Abbott&#xD;
      Vascular). Both stents are mounted on a Rapid Exchange Stent Delivery System.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Occlusive coronary artery disease is predominantly caused by coronary atherosclerosis, a&#xD;
      pathologic vascular condition characterized by abnormal lipid and fibrous tissue accumulation&#xD;
      in the vessel wall. This condition may be accompanied by degenerative changes and/or&#xD;
      calcification leading to stenosis (narrowing) of the luminal channel. Percutaneous&#xD;
      Transluminal Coronary Angioplasty (PTCA) is a well-accepted method of non-surgical myocardial&#xD;
      revascularization for selected patients with symptomatic occlusive coronary artery disease.&#xD;
&#xD;
      Restenosis is the most important challenge limiting the long-term success of coronary&#xD;
      angioplasty. Symptomatic restenosis usually occurs 6 months after an angioplasty procedure.&#xD;
      The rates of restenosis reported in numerous clinical trials vary from 13% to 57%. This&#xD;
      variability may be attributed in part to differences in the methods used to assess the&#xD;
      occurrence of restenosis and in the criteria used to define restenosis. Regardless of the&#xD;
      exact percentage, restenosis remains the Achilles heel of angioplasty. Numerous&#xD;
      pharmaceutical approaches to limit restenosis have been tested, but none have been successful&#xD;
      to date.&#xD;
&#xD;
      It was chosen to coat the stent with Titanium Nitrate (TiN), which is an inert, biocompatible&#xD;
      material, that creates a thin physical barrier to diffusion of toxic metal atoms, TiN creates&#xD;
      a very smooth surface that is impossible to obtain with a metal alloy. This coating was&#xD;
      applied to the cobalt chromium platform, &quot;Numen&quot;, made of the L605 Cobalt-20 Chromium-15&#xD;
      Tungsten-10 Nickel alloy. This alloy contains the lowest Nickel percentage of Cobalt Chromium&#xD;
      alloys used for surgical implants. The strut thickness of the platform is reduced to the&#xD;
      minimum of 65 microns for optimal hemodynamic performance and to permit an ultra low profile&#xD;
      delivery system. The &quot;Numen&quot; design complies with the requirements of the &quot;LMS -Less Mismatch&#xD;
      Stent&quot; theory applied where multiple 1 mm high zigzags form the stent pattern to align the&#xD;
      segments at 45° with respect to blood flow when the stent is expanded to its nominal&#xD;
      diameter. TiN coating is being used commercially for their hard-wearing and chemical inactive&#xD;
      properties, particularly for surgical tools. TiN features chemical stability, great hardness,&#xD;
      excellent wear properties, low electric impedance, biocompatibility, hemocompatibility and&#xD;
      the possibility, through the application process, to exchange the orientation of the grains,&#xD;
      the hardness, the wear characteristics and also the biocompatibility (a nanocrystalline&#xD;
      structure produces a chemical surface more suitable for the endothelial cells). The produced&#xD;
      coatings were very fine grained and dense with a porosity within the film structure of less&#xD;
      than 10 nm in diameter. Furthermore, in an iliac artery stent model in normal rabbits, safety&#xD;
      and efficacy in reduced restenosis of the TiN coated Numen™ stent was assessed.&#xD;
&#xD;
      The special TiN coating of the Mar-Tyn stents is very promising in reducing the lesions and&#xD;
      the causes of intima neoplasia.&#xD;
&#xD;
      This study is a multicenter (up to 8 European centers), prospective, randomized single blind&#xD;
      study. This study has a 2-arm design assessing the safety and effectiveness of the Tin-coated&#xD;
      MAR-Tyn stent to an uncoated control cobalt-chromium balloon-expandable stent (Vision, Abbott&#xD;
      Vascular), both mounted on a Rapid Exchange Stent Delivery System. A total of 160 patients&#xD;
      will be entered in the study and will be randomized on a 1:1 basis. Patients who meet the&#xD;
      eligibility criteria will be either randomized to Treatment A or Treatment B. The patient&#xD;
      will not know which stent will be implanted while the physician will be unblinded . Patients&#xD;
      will be followed at 30 days, 6, and 12 months post-procedure, with all patients undergoing&#xD;
      repeat angiography at 6 months. All adverse events up to the 1 year follow-up period will be&#xD;
      collected and analyzed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2008</start_date>
  <completion_date type="Anticipated">June 2011</completion_date>
  <primary_completion_date type="Anticipated">December 2010</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>in-stent minimum lumen diameter (MLD)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite of Major Adverse Cardiac Events (MACE) defined as death, myocardial infarction (Q wave and non-Q wave), emergent bypass surgery, thrombosis, or repeat target lesion revascularization</measure>
    <time_frame>30 days, 6 months, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic binary restenosis (&gt;50% diameter stenosis) 6 months post-procedure. In-lesion minimum lumen diameter (MLD) at 6 months post-procedure.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion revascularization (TLR) at 6 months post-procedure. Target vessel revascularization (TVR) at 6 months post-procedure.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Device success defined as achievement of a final residual diameter stenosis of &lt;30% (by QCA), using the assigned device only. If QCA is not available, the visual estimate of diameter stenosis is used.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Angioplasty, Transluminal, Percutaneous Coronary</condition>
  <condition>Stents</condition>
  <arm_group>
    <arm_group_label>A - Mar-tyn</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>It includes the implant of the Mar-tyn TiN coated stent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B - Vision</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Includes all the patients treated with the Vision stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Mar-Tyn TiN coated Co-Cr Numen stent implant</intervention_name>
    <description>Implant of the Mar-tyn TiN coated stent</description>
    <arm_group_label>A - Mar-tyn</arm_group_label>
    <other_name>Mar-Tyn</other_name>
    <other_name>martin</other_name>
    <other_name>TiN coated stent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vision Co-Cr stent implant</intervention_name>
    <description>Implant of the Vision stent</description>
    <arm_group_label>B - Vision</arm_group_label>
    <other_name>cobalt-chromium stent</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients must meet ALL of the following criteria:&#xD;
&#xD;
          1. The patient must be &gt; 18 years of age;&#xD;
&#xD;
          2. Female of childbearing potential must have a negative pregnancy test within 7 days of&#xD;
             enrollment and utilize reliable birth control for eight months after enrollment&#xD;
&#xD;
          3. Diagnosis of angina pectoris as defined by Canadian Cardiovascular Society&#xD;
             Classification (CCS I, II, III, IV) OR unstable angina pectoris (Braunwald&#xD;
             Classification B&amp;C, I-II) OR patients with documented silent ischemia;&#xD;
&#xD;
          4. Single treatment of de novo lesion in a major coronary artery in patients with single&#xD;
             or multi-vessel disease; patients with multiple lesions can be included only if the&#xD;
             other lesions do not require treatment;&#xD;
&#xD;
          5. Target vessel diameter at the lesion site is &gt;2.50mm and &lt;3.5mm in diameter (visual&#xD;
             estimate);&#xD;
&#xD;
          6. Target lesion is &gt;10mm and &lt;22mm in length (visual estimate);&#xD;
&#xD;
          7. Target lesion stenosis is &gt;50% and &lt;100% (visual estimate);&#xD;
&#xD;
          8. At least TIMI II coronary flow;&#xD;
&#xD;
          9. Acceptable candidate for coronary artery bypass surgery (CABG);&#xD;
&#xD;
         10. Patient is willing to comply with the specified follow-up evaluation;&#xD;
&#xD;
         11. Patient must provide written informed consent prior to the procedure using a form that&#xD;
             is approved by the local Ethics Committee.&#xD;
&#xD;
         12. Patient can be pre-treated with aspirin and clopidogrel or, alternatively, aspirin&#xD;
             alone plus a loading dose of 300 mg of clopidogrel before procedure completion in case&#xD;
             of urgent PCI&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients will be excluded if ANY of the following conditions apply:&#xD;
&#xD;
          1. Patient has experienced a Q-wave or non-Q-wave myocardial infarction with documented&#xD;
             total CK &gt;2 times normal within the preceding 24 hours and the CK and CK-MB enzymes&#xD;
             remains above normal at the time of treatment;&#xD;
&#xD;
          2. Has unstable angina classified as Braunwald III B or C and A I-II-III, or is having a&#xD;
             peri infarction;&#xD;
&#xD;
          3. Unprotected left main coronary disease with &gt;50% stenosis;&#xD;
&#xD;
          4. Significant (&gt;50%) stenosis proximal or distal to the target lesion that might require&#xD;
             revascularization or impede runoff;&#xD;
&#xD;
          5. Have an ostial target lesion;&#xD;
&#xD;
          6. Have a target lesion in a venous graft;&#xD;
&#xD;
          7. Angiographic evidence of thrombus within target lesion;&#xD;
&#xD;
          8. Calcified lesion which cannot be successfully predilated;&#xD;
&#xD;
          9. Documented left ventricular ejection fraction &lt;=25%;&#xD;
&#xD;
         10. Totally occluded vessel (TIMI 0 level);&#xD;
&#xD;
         11. Impaired renal function (creatinine &gt; 3.0 mg/dl) at the time of treatment;&#xD;
&#xD;
         12. Pretreatment with devices other than balloon angioplasty;&#xD;
&#xD;
         13. Target lesion has excessive tortuousity or angulation (&gt; 45°) which makes it&#xD;
             unsuitable for stent delivery and deployment;&#xD;
&#xD;
         14. Target lesion involves bifurcation including a diseased side branch &gt;=2 mm in diameter&#xD;
             (either stenosis of both main vessel and major branch or stenosis of just major&#xD;
             branch) that would require side branch stenting;&#xD;
&#xD;
         15. Prior stent within 5mm of target lesion;&#xD;
&#xD;
         16. Direct Stenting&#xD;
&#xD;
         17. Recipient of heart transplant;&#xD;
&#xD;
         18. Patient with a life expectancy less than 12 months;&#xD;
&#xD;
         19. Known allergies to the following: aspirin, clopidogrel bisulfate (Plavix) and&#xD;
             ticlopidine (Ticlid), heparin, cobalt, chromium, or contrast agent (that cannot be&#xD;
             managed medically)&#xD;
&#xD;
         20. Recent (6 months) cerebrovascular accidents or intracranial hemorrhage&#xD;
&#xD;
         21. Any significant medical condition which in the investigator's opinion may interfere&#xD;
             with the patient's optimal participation in the study;&#xD;
&#xD;
         22. Currently participating in an investigational drug or another device study;&#xD;
&#xD;
         23. Intervention of another lesion has occurred within 6 months before the index&#xD;
             procedure;&#xD;
&#xD;
         24. In the investigator's opinion, the lesion is not suitable for stenting.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marco Balducelli, MD,FESC,FACC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale &quot;S.Maria delle Croci&quot; - Ravenna, Italy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Luigi Marras, Dr. MEng. PhD.</last_name>
    <phone>+39 3346738578</phone>
    <email>luigi.marras@ibsmed.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nader Shehata, Dr. Eng.</last_name>
    <phone>+39 040 3755 639</phone>
    <email>Nader.shehta@ibsmed.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Internal Medicine III (Cardiology), University of Freiburg im Breisgau</name>
      <address>
        <city>Freiburg Im Breisgau</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christoph Hehrlein, Prof. MD</last_name>
      <email>hehrlein@Medizin.Ukl.Uni-Freiburg.De</email>
    </contact>
    <investigator>
      <last_name>Christoph Hehrlein, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario di Bari-Emodinamica Interventista</name>
      <address>
        <city>Bari</city>
        <state>BA</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bortone</last_name>
      <email>abortone@cardiochir.uniba.it</email>
    </contact>
    <investigator>
      <last_name>Alessandro Bortone, Dr. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele- Emodinamica e Cardiologia</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Colombo, Dr. MD</last_name>
      <email>colombo.antonio@hsr.it</email>
    </contact>
    <investigator>
      <last_name>Antonio Colombo, Dr. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale di Ravenna, U.O. Cardiologia</name>
      <address>
        <city>Ravenna</city>
        <state>Ra</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marco Balducelli, Dr. MD</last_name>
      <phone>+39 0544 285 388</phone>
      <email>ra.hocardioemo@ausl.ra.it</email>
    </contact>
    <investigator>
      <last_name>Marco Balducelli, Dr. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Campus Biomedico, Cardiologia</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Germano Di Sciascio, Dr. MD</last_name>
      <phone>+39 06225411</phone>
      <email>g.disciascio@unicampus.it</email>
    </contact>
    <investigator>
      <last_name>Germano Di Sciascio, Dr. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CARIM, Department of Cardiology</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J. Waltenberger, Prof. MD</last_name>
      <email>j.waltenberger@cardio.azm.nl</email>
    </contact>
    <investigator>
      <last_name>J. Waltenberger, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cardiocentro Ticino, Cardiologia</name>
      <address>
        <city>Lugano</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tiziano Moccetti</last_name>
      <email>tiziano.moccetti@cardiocentro.org</email>
    </contact>
    <investigator>
      <last_name>Tiziano Moccetti, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Switzerland</country>
  </location_countries>
  <removed_countries>
    <country>France</country>
  </removed_countries>
  <verification_date>February 2010</verification_date>
  <study_first_submitted>March 10, 2008</study_first_submitted>
  <study_first_submitted_qc>March 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2008</study_first_posted>
  <last_update_submitted>February 8, 2010</last_update_submitted>
  <last_update_submitted_qc>February 8, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2010</last_update_posted>
  <responsible_party>
    <name_title>prof. Aleardo Maresta</name_title>
    <organization>Head of Cardiology Department - S.Maria delle Croci Hospital, Ravenna (Italy)</organization>
  </responsible_party>
  <keyword>percutaneous transluminal coronary angioplasty</keyword>
  <keyword>stents</keyword>
  <keyword>restenosis</keyword>
  <keyword>biocompatible materials</keyword>
  <keyword>ceramics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chromium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

